Literature DB >> 3690842

Bias and precision of cholesterol analysis by physician's office analyzers.

T R Koch1, U Mehta, H Lee, K Aziz, S Temel, J A Donlon, R Sherwin.   

Abstract

We studied the bias and precision of serum cholesterol analysis by physician's office analyzers. Total imprecision (CV range, %) for analysis of serum pools was: Abbott Vision 1.5%-1.9%; Ames Seralyzer 3.9%-4.5%; BMD Reflotron 2.3%-3.8%; Chrometrics Cholesterol Test System 2.3%-2.8%; Kodak DT-60 1.6%-2.2%. The Ames Seralyzer exhibited an excessive between-run component of variation. We collected, from 109 volunteers, samples of venous serum, heparin-treated whole blood, heparin-treated plasma, and fingerstick whole blood, and analyzed each type (where possible) with each system; serum was also analyzed in duplicate (by a proposed Reference Method) at the Centers for Disease Control. For assays with serum, the BMD Reflotron and Kodak DT-60 exhibited negative bias. All systems gave lower results for plasma and whole blood than for serum. All systems except the Kodak DT-60 were less precise for analysis of patients' sera than for analysis of serum pools; between-specimen variables may influence the results of these systems.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3690842

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  8 in total

Review 1.  Systematic review of near patient test evaluations in primary care.

Authors:  B C Delaney; C J Hyde; R J McManus; S Wilson; D A Fitzmaurice; S Jowett; R Tobias; G H Thorpe; F D Hobbs
Journal:  BMJ       Date:  1999-09-25

2.  Performance of the Reflotron in Massachusetts' Model System for Blood Cholesterol Screening Program.

Authors:  S Havas; R Bishop; L Koumjian; J Reisman; S Wozenski
Journal:  Am J Public Health       Date:  1992-03       Impact factor: 9.308

3.  A comparison of results of a national cholesterol and blood pressure screening with the NHANES II Study: implications for further emphasis on reducing cardiovascular risk among Americans.

Authors:  F W Fridinger; A W Jackson; J Andresen
Journal:  J Community Health       Date:  1992-08

4.  One state's approach to the regulation of cholesterol screening.

Authors:  J M DeBoy
Journal:  Public Health Rep       Date:  1990 Nov-Dec       Impact factor: 2.792

Review 5.  Screening for presymptomatic disease.

Authors:  F V Flynn
Journal:  J Clin Pathol       Date:  1991-07       Impact factor: 3.411

6.  Precision and accuracy of a portable blood analyzer system during cholesterol screening.

Authors:  P Greenland; N L Bowley; C A French; B Meiklejohn; S Gagliano; C E Sparks
Journal:  Am J Public Health       Date:  1990-02       Impact factor: 9.308

7.  Quality of plasma cholesterol measurements in primary care.

Authors:  P M Broughton; D G Bullock; R Cramb
Journal:  BMJ       Date:  1989-02-04

8.  Comparison of the use of a dry chemistry analyser in primary care in Norway and the United Kingdom.

Authors:  G Thue; S Sandberg; D G Bullock
Journal:  Br J Gen Pract       Date:  1993-01       Impact factor: 5.386

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.